Intercure (INCR) director Gideon Hirschfeld reports existing stock option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Intercure Ltd. director Gideon Hirschfeld reported his existing holdings of stock options on the company’s ordinary shares. This Form 3 shows two option grants, both held directly, with different exercise prices, vesting terms, and expiration dates.
One option grant covers 4,046 underlying ordinary shares with an exercise price of $8.22 per share, expiring on January 9, 2030. These options were granted on January 9, 2020 and became fully vested on January 9, 2023. A second grant covers 15,000 underlying ordinary shares with an exercise price of $3.10 per share, expiring on September 5, 2028, and vests quarterly over four years from the September 5, 2024 grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Hirschfeld Gideon
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share options (right to buy) | -- | -- | -- |
| holding | Share options (right to buy) | -- | -- | -- |
Holdings After Transaction:
Share options (right to buy) — 4,046 shares (Direct)
Footnotes (1)
- The options were granted on January 9, 2020, and the current exercise price is NIS 25.146 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026, resulting in an exercise price of $8.22 per share. The options became fully vested as of January 9, 2023. The options were granted on September 5, 2024, and the current exercise price is NIS 9.50 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026, resulting in an exercise price of $3.1 per share. The options vest on a quarterly basis over four years from the date of grant.
Key Figures
Option grant 1 underlying shares: 4,046 shares
Option grant 1 exercise price: $8.22 per share
Option grant 1 expiration: January 9, 2030
+5 more
8 metrics
Option grant 1 underlying shares
4,046 shares
Ordinary Shares underlying options granted January 9, 2020
Option grant 1 exercise price
$8.22 per share
Converted from NIS 25.146 at NIS 3.06 = USD $1.00
Option grant 1 expiration
January 9, 2030
Expiration date for 4,046-share option grant
Option grant 2 underlying shares
15,000 shares
Ordinary Shares underlying options granted September 5, 2024
Option grant 2 exercise price
$3.10 per share
Converted from NIS 9.50 at NIS 3.06 = USD $1.00
Option grant 2 expiration
September 5, 2028
Expiration date for 15,000-share option grant
Exchange rate used
NIS 3.06 = USD $1.00
Rate used to convert NIS exercise prices as of April 14, 2026
Vesting completion date grant 1
January 9, 2023
Date options from 2020 grant became fully vested
Key Terms
Share options (right to buy), Ordinary Shares, exercise price, vested, +2 more
6 terms
exercise price financial
"resulting in an exercise price of $8.22 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"The options became fully vested as of January 9, 2023."
exchange rate financial
"using an exchange rate of NIS 3.06 to USD $1.00"
Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.
Form 3 regulatory
"For purposes of this Form 3, the exercise price has been converted"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
What does Gideon Hirschfeld’s Form 3 for Intercure (INCR) report?
The Form 3 reports Gideon Hirschfeld’s existing holdings of Intercure stock options. It lists two direct option grants on ordinary shares, detailing their exercise prices, expiration dates, and vesting schedules, but does not show any new purchases or sales.
What are the exercise prices of Gideon Hirschfeld’s Intercure options?
One option grant has an exercise price of $8.22 per share and another has an exercise price of $3.10 per share. These U.S. dollar amounts result from converting original NIS exercise prices using a disclosed NIS 3.06 to USD $1.00 exchange rate.
When do Gideon Hirschfeld’s Intercure stock options expire?
One grant expires on January 9, 2030, while the other expires on September 5, 2028. These expiration dates define the final dates by which the respective options on Intercure’s ordinary shares can be exercised, assuming vesting conditions are met.
How do Gideon Hirschfeld’s Intercure options vest over time?
The options granted on January 9, 2020 are fully vested as of January 9, 2023. The options granted on September 5, 2024 vest on a quarterly basis over four years from the grant date, gradually increasing the number of exercisable options each quarter.
How were the Intercure option exercise prices converted into U.S. dollars?
The filing states that the current NIS exercise prices were converted using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026. This conversion produced U.S. dollar exercise prices of $8.22 and $3.10 per Intercure ordinary share.